

ASX RELEASE

Introduction to Katherine Singson – webinar recording

Wellington, NZ, 7th August 2020: [Volpara Health Technologies](#) (“Volpara,” “the Group,” or “the Company”; ASX: VHT), a medical technology company whose cancer screening software assists in the delivery of personalised patient care, is pleased to share a recording of its webinar held this week, discussing plans to accelerate digital marketing in the US, and introducing Katherine Singson, newly appointed CEO of Volpara Solutions Inc.

Joined by Group CEO Dr Ralph Highnam, Katherine spoke about:

- Her 30+ year experience in strategy, sales and marketing with companies including NeXT, Apple and Pixar, working directly with Steve Jobs, and later with Microsoft ANZ
- Her own experience as a breast cancer survivor and commitment to revolutionising breast cancer detection and care
- The significant opportunity for Volpara to drive further adoption in the US through digital marketing

A recording of the session is now available on Volpara’s website:

<https://www.volparasolutions.com/investor-information/company-interviews/>

Annual General Meeting

A reminder that the Company’s AGM will be held at 10:00am AEST (12:00pm NZST) on Wednesday 19th August 2020 in Wellington, New Zealand.

You can access the event virtually using this link:

https://us02web.zoom.us/webinar/register/WN_uA5oBSOoRya0MFfmcc2_fQ

Once registered, you will receive Zoom access details and alternative phone dial-ins.

ENDS.

Authorisation and Additional Information

This announcement was authorised by the CEO Dr Ralph Highnam.

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Trevor Chappell
WE Communications
WE-AUVolpara@we-worldwide.com
t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020. VHT is based in Wellington, New Zealand.

At the end of June 2019, VHT acquired MRS Systems, Inc., a company based in Seattle, WA. MRS provides mammography reporting systems to over 1,600 breast clinics and hospitals, and to VHT a much stronger US presence, experienced local headquarters, and accelerated sales through cross-selling opportunities.

For more information, visit www.volparasolutions.com